Report cover image

Global Heavy Metal Poisoning Treatment Market - 2023-2030

Publisher DataM Intelligence 4Market Research LLP
Published Mar 26, 2024
Length 189 Pages
SKU # DTAM18651883

Description

Global Heavy Metal Poisoning Treatment Market - 2023-2030


Global heavy metal poisoning treatment market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.

Heavy metal poisoning is a medical condition that occurs when toxic heavy metals accumulate in the body. These metals, such as lead, mercury, cadmium, and arsenic, can enter the body through contaminated food, water, or exposure to certain occupations. The symptoms experienced and the severity of the poisoning depends on the type of metal involved and the level of exposure. Some common symptoms include neurological and cognitive problems, digestive issues, organ damage, and in severe cases, death.

The treatment for heavy metal poisoning varies depending on the specific metal involved and the severity of the poisoning. One common approach is chelation therapy, which involves administering chelating agents such as dimercaprol, DMSA, or EDTA.

Market Dynamics: Drivers and Restraints

The development of novel oral treatments for heavy metal poisoning is expected to drive the market growth

In 2022, the biotech startup HOPO Therapeutics, based in Berkeley, was co-founded by Hannah Weber, an MBA/MPH student at Berkeley Haas, along with scientists Julian Rees and Rebecca Abergel from Lawrence Berkeley National Laboratory. Their mission is to develop effective treatments for heavy metal poisoning. Their first product, called HOPO-101, is an innovative oral treatment designed to selectively bind to toxic metals, facilitating their safe removal from the body without affecting essential minerals.

Lead poisoning affects over 800 million children worldwide. HOPO Therapeutics is addressing this global health issue by planning to begin Phase 1 clinical trials soon. They aim to secure venture funding to support their mission of providing accessible, life-saving treatments for heavy metal poisoning. The company is seeking partnerships with physicians, governments, impact investors, and global health organizations to maximize their impact and distribution.

Furthermore, the high prevalence of heavy metal exposure, ongoing research and development, and governments and international organizations launching public health initiatives to combat heavy metal poisoning are the factors expected to drive the market over the forecast period.

Restraint:

Lack of awareness among the general population, high treatment costs and environmental challenges are the factors expected to hamper the market over the forecast period.

For more details on this report – Request for Sample

Segment Analysis

The global heavy metal poisoning treatment market is segmented based on the type of heavy metal poisoning, treatment, route of administration, distribution channel and region.

The chelating agents from the treatment segment accounted for approximately 43.4% of the heavy metal poisoning treatment market share

Chelating agents are essential in the treatment of heavy metal poisoning, as they facilitate the removal of toxic metals from the body. These agents work by binding to heavy metals in the bloodstream, forming stable complexes that can be excreted through urine. This process helps reduce the concentration of harmful metals and mitigates their adverse effects on organs and tissues.

Chelating agents have several advantages, including their ability to selectively target toxic metals, sparing essential minerals, and reducing the risk of side effects. The market for chelating agents in heavy metal poisoning treatment is driven by factors such as the increasing awareness of heavy metal health risks, and a growing patient population suffering from heavy metal exposure.

For instance, National Lead Poisoning Prevention Week (NLPPW) is an annual event that aims to increase awareness of lead poisoning. The event brings together individuals, organizations, industry, and state, tribal, and local governments to reduce childhood exposure to lead. NLPPW is usually held in October, which is also Children's Health Month - a time to raise awareness about children's environmental health, including the dangers and potential health impacts of lead.

Geographical Analysis

North America accounted for approximately 42.1% of the market share in 2022

North America is expected to hold the largest market share, owing to the increasing acquisition, rising investment in the chelating agents, and growing product launches by the companies.

For instance, on August 10, 2022, Captura Biopharma a biotech company is developing and commercializing oral chelators to treat internal transuranic radionuclide contamination and heavy metal poisoning.

Exposure to these contaminants has been linked to severe health issues, including heart disease and cancer. Although the U.S. Environmental Protection Agency (EPA) has established maximum contaminant levels for these metals, they acknowledge that there is no safe level of exposure to either. Therefore, this research highlights the urgent necessity for accessible and targeted treatments to mitigate the health impacts of heavy metal exposure and emphasizes the importance of public health initiatives to address these disparities effectively.

COVID-19 Impact Analysis

The COVID-19 pandemic had several notable impacts on the heavy metal poisoning treatment market. Exposure to heavy metals can increase the risk of COVID-19 and other respiratory infections. Both smoking and PM2.5 pollution are associated with toxic metals that can cause respiratory dysfunction, immunotoxicity, and worsen viral diseases. People with HIV and those at high risk have higher levels of heavy metals in their bodies. A study on COVID-19 patients found that deceased cases had higher levels of cadmium in their blood.

Moreover, lockdowns, restrictions, and patient concerns about visiting healthcare facilities also led to delays in screenings and diagnoses. As heavy metal poisoning symptoms can be vague, these delays hindered early detection and intervention. In addition, the pandemic also affected research and development efforts related to new and improved heavy metal poisoning treatments. Clinical trials and drug development projects faced delays and setbacks, slowing the introduction of innovative treatment options. Despite the challenges, it is important to address heavy metal poisoning. The market is expected to recover as healthcare systems stabilize and R&D efforts regain momentum.

Market Segmentation:

By Type of Heavy Metal Poisoning
• Lead
• Mercury
• Arsenic
• Cadmium
• Thallium
• Aluminum
• Barium
• Others

By Treatment
• Chelating Agents
D-Penicillamine
• Medications
Dimercaprol
Dimercaptosuccinic acid (succimer)
Ethylenediaminetetraacetic acid (EDTA)
Penicillamine
• Others

By Route of Administration
• Parenteral Route
• Oral Route
• Others

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the heavy metal poisoning treatment market include SGPharma Pvt. Ltd., HOPO Therapeutics, Inc., Yashica Pharmaceuticals Private Limited., EmeraMed Limited, Captura Biopharma, Bausch Health Companies Inc., Midas Pharma GmbH, Recordati Rare Diseases Inc, and Lupin Pharmaceuticals, Inc. among others.

Key Development
• On August 10, 2022, Captura Biopharma and OceanTech Acquisitions I Corp. entered into a definitive business combination agreement that will result in Captura Biopharma becoming a publicly listed company on The Nasdaq Stock Market LLC. Captura Biopharma is an emerging biotechnology company that develops and commercializes oral chelators to treat internal transuranic radionuclide contamination and heavy metal poisoning. Upon completion of the transaction, OceanTech will be renamed Captura Biopharma Holdings, Inc. (the ""Combined Company"").
• On August 10, 2023, Rising Pharmaceuticals, an affiliate of Rising Pharma Holdings Inc., launched Edetate calcium disodium injection in the United States. The launch is aimed at addressing a critical shortage of this important therapy.

Why Purchase the Report?
• To visualize the global heavy metal poisoning treatment market segmentation based on type of heavy metal poisoning, treatment, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of heavy metal poisoning treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global heavy metal poisoning treatment market report would provide approximately 66 tables, 71 figures, and 189 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

189 Pages
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type of Heavy Metal Poisoning
3.2. Snippet by Treatment
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The development of novel oral treatments for heavy metal poisoning
4.1.2. Restraints
4.1.2.1. The high cost of treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. SWOT Analysis
5.7. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type of Heavy Metal Poisoning
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Heavy Metal Poisoning
7.1.2. Market Attractiveness Index, By Type of Heavy Metal Poisoning
7.2. Lead*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Mercury
7.4. Arsenic
7.5. Cadmium
7.6. Thallium
7.7. Aluminum
7.8. Barium
7.9. Others
8. By Treatment
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment
8.2. Chelating Agents*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.2.1. D-Penicillamine
8.3. Medications
8.3.1.1. Dimercaprol
8.3.1.2. Dimercaptosuccinic acid (succimer)
8.3.1.3. Ethylenediaminetetraacetic acid (EDTA)
8.3.1.4. Penicillamine
8.4. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral Route*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Parenteral Route
9.4. Others
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Heavy Metal Poisoning
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Heavy Metal Poisoning
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Spain
11.3.7.5. Italy
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Heavy Metal Poisoning
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Heavy Metal Poisoning
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Heavy Metal Poisoning
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. SGPharma Pvt. Ltd.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. HOPO Therapeutics, Inc.
13.3. Yashica Pharmaceuticals Private Limited.
13.4. EmeraMed Limited
13.5. Captura Biopharma
13.6. Bausch Health Companies Inc.
13.7. Midas Pharma GmbH
13.8. Recordati Rare Diseases Inc
13.9. Lupin Pharmaceuticals, Inc.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us